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Abstract
Background: Streptococcus suis is a major swine pathogen worldwide that causes meningitis, septicemia, arthritis,
and endocarditis. Using animal models, a surface-associated subtilisin-like protease (SspA) has recently been shown
to be an important virulence factor for S. suis. In this study, we hypothesized that the S. suis SspA subtilisin-like
protease may modulate cytokine secretion by macrophages thus contributing to the pathogenic process of
meningitis.
Results: Phorbol 12-myristate 13-acetate-differentiated U937 macrophages were stimulated with recombinant SspA
prior to monitor cytokine secretion by ELISA. Our results indicated that the recombinant SspA was able to dose-
dependently induce IL-1b, IL-6, TNF-a, CXCL8 and CCL5 secretion in macrophages. The heat-inactivated protease
was still able to induce cytokine secretion suggesting a non-proteolytic mechanism of macrophage activation.
Using specific kinase inhibitors, evidence were bought that cytokine secretion by macrophages stimulated with the
recombinant SspA involves the mitogen-activated protein kinase signal transduction pathway. While stimulation of
macrophages with low concentrations of recombinant SspA was associated to secretion of high amounts of CCL5,
the use of recombinant SspA at a high concentration resulted in low amounts of CCL5 detected in the
conditioned medium. This was found to be associated with a proteolytic degradation of CCL5 by SspA. The ability
of SspA to induce cytokine secretion in macrophages was confirmed using a mutant of S. suis deficient in SspA
expression.
Conclusion: In conclusion, this study identified a new mechanism by which the S. suis SspA may promote central
nervous system inflammation associated with meningitis.
Background
Streptococcus suis is a major swine pathogen worldwide
that causes meningitis, septicemia, arthritis, and endo-
carditis [1]. S. suis infections in humans remain sporadic
and affect mainly individuals in close contact with sick
or carrier pigs or pig-derived products, typically pig
farmers, veterinary personnel, abattoir workers, and
butchers [2]. However, the important outbreak that
occurred in China in 1998 and 2005 modified the world
perspective regarding the threat of S. suis for humans
[3,4]. S. suis is transmitted via the respiratory route and
colonizes the palatine tonsils of pigs. While 35 serotypes
(1 to 34 and 1/2) have been identified, serotype 2 is con-
sidered the most frequently associated with pathology
[5], although other serotypes are also the source of
many infections [6-8].
Various potential virulence factors produced by S. suis
have been identified, including a sialic acid-rich capsule
[9], an hemolysin (suilysin) [10], adhesins [11,12], and pro-
teolytic enzymes [13,14]. Our laboratory recently reported
on the cloning of a 170 kDa subtilisin-like protease (SspA)
found on the cell surface of S. suis [15]. This protease was
found to possesses a high protein cleavage specificity and
can degrade the Aa chain of fibrinogen thus preventing
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models and deficient-mutants, the surface-associated SspA
was found to play a key role as virulence factor for S. suis
[16,17]. However, the exact contribution of the SspA in
t h ep a t h o g e n i cp r o c e s so fS. suis infections has not been
clearly defined.
To cause meningitis, S. suis must first cross the muco-
sal barrier, enter the bloodstream, resist to host defense
mechanisms in the intravascular space, invade the
blood-brain barrier, and then replicate in the subarach-
noidal space [18]. Once the bacteria reach the blood-
brain barrier, the secretion of proinflammatory cyto-
kines, by host cells may contribute to increasing the per-
meability of this barrier [18-20]. A number of studies
have reported that S. suis can induce the secretion of
high amounts of proinflammatory cytokines by host
cells, including monocytes/macrophages [19-21]. This
excessive production of proinflammatory cytokines has
been suggested to play a key role in pathogenesis of
both systemic and central nervous system infections and
to contribute to the pathogenic processes of meningitis
[22,23]. The aim of this study was to investigate the
capacity of the S. suis SspA subtilisin-like protease to
modulate cytokine secretion by macrophages.
Methods
Strains and growth conditions
S. suis P1/7 (serotype 2) as well as a SspA deficient
mutant (G6G) were used in this study. Mutant G6G was
selected from a mutant library constructed using the
pTV408 temperature-sensitive suicide vector to deliver
the Tn917 transposon into S. suis P1/7 via electropora-
tion [16]. This mutant is unable to degrade the chromo-
genic substrate (N-succinyl-Ala-Ala-Pro-Phe-pNa;
Sigma-Aldrich Canada Ltd., Oakville, ON, CANADA)
specific for subtilisin-like proteases and showed a single
Tn917 insertion into the gene coding for the SSU0757
protein in the genome of S. suis P1/7 [16]. Bacteria were
grown at 37°C in Todd Hewitt broth (THB; BBL Micro-
biology Systems, Cockeysville, MA, USA).
Preparation of recombinant SspA of S. suis
The subtilisin-like protease SspA of S. suis was cloned,
purified, and characterized in a previous study [15].
Briefly, the SSU0757 gene encoding the SspA was ampli-
fied and a 4,798-bp DNA fragment was obtained. It was
cloned into the expression plasmid pBAD/HisB and
then inserted into Escherichia coli to overproduce the
protein. The recombinant protease was purified by chro-
matography procedures and showed a molecular weight
of 170 kDa. Using a chromogenic Limulus amebocyte
lysate assay (Associates of Cape Cod, Inc., East Fal-
mouth, MA), the SspA preparation was found to contain
less than 5 ng endotoxin/ml.
Cultivation of monocytes and preparation of
macrophage-like cells
The monoblastic leukemia cell line U937 (ATCC CRL-
1593.2; American Type Culture Collection, Manassas,
VA, USA) was cultivated at 37°C in a 5% CO2 atmo-
sphere in RPMI-1640 medium (HyClone Laboratories,
Logan, UT, USA) supplemented with 10% heat-inacti-
vated fetal bovine serum (FBS; RPMI-FBS) and 100 μg/
ml penicillin-streptomycin. Monocytes (2 × 10
5 cells/ml)
were incubated in RPMI-FBS containing 10 ng/ml of
phorbol 12-myristic 13-acetate (PMA) for 48 h to
induce differentiation into adherent macrophage-like
cells [24]. Following the PMA treatment, the medium
was replaced with fresh medium and differentiated
macrophages were incubated for an additional 24 h
prior to use. Adherent macrophages were suspended in
RPMI-FBS and centrifuged at 200 × g for 5 min. The
cells were washed, suspended at a density of 1 × 10
6
cells/ml in RPMI supplemented with 1% heat-inactivated
FBS and seeded in a 96 well-plate (1 × 10
6 cells/well/0.2
m l )a t3 7 ° Ci n5 %C O 2 atmosphere for 2 h prior to
treatments.
Treatment of macrophages
PMA-differentiated U937 macrophages were treated
with recombinant SspA at concentrations ranging from
0.00033 to 33 μg/ml. Stimulation was also performed
using the recombinant SspA treated at 100°C for 30 min
to inactivate the catalytic activity or in the presence of
polymyxin B (1 μg/ml) to exclude any contribution of
contaminating LPS in macrophage stimulation. As a
control, pancreatic trypsin (Sigma-Aldrich Canada Ltd.)
was used in the same range of concentrations (0.00033
to 33 μg/ml). Lastly, PMA-differentiated U937 macro-
phages were also stimulated with S. suis P1/7 and G6G
cells at a multiplicity of infection (MOI) of 100. All
treatments were carried out for 18 h in a 5% CO2
atmosphere.
Determination of macrophage viability
Following treatments with either the recombinant SspA
or bacterial cells, cell viability was evaluated with an
MTT (3-[4,5-diethylthiazol-2-yl]-2,5-diphenyltetrazolium
bromide) test performed according to the manufac-
turer’s protocol (Roche Diagnostics, Mannheim,
Germany).
Determination of cytokine secretion
Commercial enzyme-linked immunosorbent assay
(ELISA) kits (R&D Systems, Minneapolis, MN, USA)
were used to quantify IL-1b,I L - 6 ,T N F - a, CCL5, and
CXCL8 concentrations in the cell-free culture superna-
tants according to the manufacturer’sp r o t o c o l s .T h e
absorbance at 450 nm was read using a microplate
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The rated sensitivities of the commercial ELISA kits
were 3.9 pg/ml for IL-1b, 9.3 pg/ml for IL-6, 15.6 pg/ml
for TNF-a and CCL5, and 31.2 pg/ml for CXCL8.
Determination of cytokine degradation
Degradation of IL-6, CXCL8, and CCL5 by the recombi-
nant SspA was assessed by ELISA. Briefly, recombinant
cytokines (300 pg/ml of IL-6, 250 pg/ml of CXCL8, or
500 pg/ml of CCL5,) were incubated with the recombi-
nant SspA at concentrations ranging from 0.26 to 16.5
μg/ml for 4 h. Following incubation, residual cytokines
were quantified by ELISA as described above.
Effect of kinase inhibitors on cytokine secretion
Specific kinase inhibitors (Calbiochem, Mississauga, ON,
Canada) used at the optimal concentration recom-
mended by the manufacturer (0.0625 μM) were added
to macrophages 2 h prior to being treated with the
recombinant SspA (0.33 μg/ml) for 18 h. The inhibitors
SB203580 [p38 mitogen-activated kinase (p38MAPK)
inhibitor], UO126 [mitogen-activated extracellular
kinase 1, 2 (MEK 1, 2) inhibitor] and JNK inhibitor II
[c-JUN N-terminal kinase (JNK) inhibitor], were evalu-
ated for their effect on IL-6, CXCL8, and CCL5 secre-
tion by macrophages.
Statistical analysis
All treatments and cytokine determination were per-
formed in triplicate and the means ± standard deriva-
tions were calculated. Differences were analyzed for
statistical significance using the Student’st - t e s ta n d
were considered significant at P < 0.01.
Results
Prior to determine the capacity of the recombinant SspA
of S. suis to induce an inflammatory response in PMA-
differentiated U937 macrophages, its effect on cell viabi-
lity was evaluated. The MTT test revealed that macro-
phage viability was not significantly reduced (less than
20%) by a treatment with the recombinant SspA at a
concentration of up to 33 μg/ml. As reported in Figure
1A-C, a significant dose-dependent secretion of all three
pro-inflammatory cytokines IL-1b,I L - 6a n dT N F - a was
observed following stimulation of macrophages with the
recombinant SspA. More specifically, treatment of
macrophages with SspA at 0.33 μg/ml resulted in a 2-
fold, 55-fold and 7-fold increase of IL-1b,I L - 6a n d
TNF-a levels, respectively. In addition, there was a sig-
nificant dose-dependent increase of CXCL8 and CCL5
secretion by macrophages stimulated with the recombi-
nant SspA. The levels of CXCL8 (Figure 1D) increased
by 17-fold while that of CCL5 (Figure 1E) increased by
15-fold when the recombinant SspA was used at 0.33
μg/ml (Figure 1D-E). In contrast, when the macrophages
were stimulated with pancreatic trypsin instead of
recombinant SspA, no increase in cytokine secretion
was observed (Figure 1). When macrophages were sti-
mulated with the recombinant SspA at the highest con-
centration (33 μg/ml), a very low amount of CCL5,
which correspond to that of non-stimulated macro-
phages was detected. This decrease in cytokine produc-
tion was also observed for IL-6 but to a much lesser
extent (Figure 1B).
The effect of stimulating macrophages with heat-inac-
tivated recombinant SspA or with active SspA in the
presence of polymyxin (LPS neutralizing molecule) on
the secretion of IL-6, CXCL8 and CCL5, the three cyto-
kines produced in higher amounts by macrophages, was
then tested. As reported in Table 1, the secretion of IL-
6 and CXCL8 was significantly increased after stimula-
tion of macrophages with the active recombinant SspA
(33 μg/ml) while only a slight increase was observed in
the case of CCL5. The amounts of IL-6 and CXCL8
produced by macrophages were not markedly different
when the recombinant SspA of S. suis was inactivated
by heat treatment (30 min at 100°C). However, stimula-
tion of macrophages with the heat-inactivated SspA was
associated with a significantly higher amount of CCL5
in the conditioned culture medium compared to the
treatment with the active recombinant SspA (72409 ±
848 versus 2370 ± 61 pg/ml). Lastly, the presence of
polymyxin B during stimulation of macrophages with
the recombinant SspA protease had no significant effect
on the levels of cytokine produced. The efficacy of poly-
myxin B (1 μg/ml) in neutralizing the inflammatory
activity of Escherichia coli LPS was demonstrated in pre-
liminary assays.
To further support the inflammatory property of the
recombinant SspA, we compared the SspA-deficient
mutant G6G and the parental strain for their capacity to
induce of IL-1b,T N F - a, IL-6, CXCL8 and CCL5 secre-
tion in macrophages. The MTT test revealed that
macrophage viability was not significantly reduced (less
than 10%) by a treatment with cells of S. suis P1/7 or
G6G at MOI of 100. As reported in Table 2, the
amounts of IL-1b,T N F - a and IL-6 secreted by macro-
phages were significantly lower for the SspA-deficient
mutant compared to the parental strain. More specifi-
cally, IL-1b, TNF-a and IL-6 production were decreased
by 26%, 43% and 41%, respectively. In contrast, the
amounts of CCL5 and to a lesser extent CXCL8 were
significantly higher when macrophages were stimulated
with SspA-deficient mutant (G6G) compared to the par-
ental strain.
Lastly we investigated the capacity of the SspA pro-
tease to degrade CCL5, IL-6 and CXCL8, the tree cyto-
kines produced in higher amounts by macrophages
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cytokines were incubated with the SspA protease at
concentrations ranging from 0.26 to 16.5 μg/ml and
after 4 h, residual cytokines were determined by ELISA
(Figure 2). There was a significant decrease in amounts
of CCL5 in presence of SspA, even at low concentra-
tions (0.26 μg/ml). Moreover, a decrease of approxi-
mately 20% was also noticed for IL-6 treated with SspA
at 16.5 μg/ml. In contrast, there was no decrease for
CXCL8 following incubation with SspA.
0
50
100
150
200
Control 0.00033 0.0033 0.033 0.33 3.3 33
I
L
-

ȕ


S
J

P
O
 Recombinant SspA Trypsin
0
500
1000
1500
2000
Control 0.00033 0.0033 0.033 0.33 3.3 33
T
N
F
-
Į


S
J

P
O

* C *
*
*
*
0
10000
20000
30000
40000
Control 0.00033 0.0033 0.033 0.33 3.3 33
C
C
L
5
 
(
p
g
/
m
l
)
0
100
200
300
400
500
600
Control 0.00033 0.0033 0.033 0.33 3.3 33
I
L
-
6
 
(
p
g
/
m
l
)
E
A
*
* * *
B
*
*
* *
*
0
15000
30000
45000
60000
75000
90000
105000
Control 0.00033 0.0033 0.033 0.33 3.3 33
C
X
C
L
8
 
(
p
g
/
m
l
) D
*
*
*
* *
*
*
* *
*
Amount of protease (μg/ml)
Figure 1 Cytokine secretion by PMA-differentiated U937 macrophages stimulated with the recombinant SspA of S. suis or with
pancreatic trypsin. Following stimulation (18 h) with various amounts of proteases, the secretion of IL-1b (panel A), IL-6 (panel B), TNF-a (panel
C), CXCL8 (panel D) and CCL5 (panel E) was assessed by ELISA. The data are the means ± SD of triplicate assays from three separate
experiments. Asterisks indicate a significant difference in comparison with the non-stimulated macrophages at P < 0.01.
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which the recombinant SspA may activate macrophages,
the effect of selected kinase inhibitors on the secretion
of IL-6, CXCL8 and CCL5 by macrophages was investi-
gated. As reported in Figure 3, a complete inhibition of
CCL5 and CXCL8 secretion was observed in the pre-
sence of SB203580, an inhibitor specific to p38 mitogen-
activated kinase (p38 MAPK). The secretion of IL-6 by
this kinase inhibitor was decreased by 28% while it was
decreased by 85% with the JNK inhibitor.
Discussion
S. suis is a swine pathogen responsible for several infec-
tions including meningitidis, endocarditis and septice-
miae, and is also an important agent for zoonosis [1].
Recently, a subtilisin-like protease, named SspA, was
identified as a virulence factor in S. suis. This was based
on the fact that SspA deficient mutants were signifi-
cantly less pathogenic in animal models [16,17]. In the
present study, we sought to determine the capacity of S.
suis SspA to induce an inflammatory response in U937
macrophages.
We showed that recombinant SspA induced the secre-
tion of IL-1b,T N F - a, IL-6, CXCL8 and CCL5 by
macrophages. This significant cytokine secretion may be
of utmost importance in S. suis-induced meningitis.
Indeed, Lopes-Cortes et al., demonstrated that IL-1b
and TNF-a are present in the cerebrospinal fluid and
that high levels of these cytokines correlate with the
neurological complications [25]. More specifically, IL1-b
can enhance the permeability of the blood-brain barrier
[26]. Moreover, high levels in local body fluids and in
s e r u mo fI L - 6a n dT N F - a are associated with a fatal
outcome [27]. Moller et al., also reported that the cere-
brospinal fluid of patients suffering from bacterial
meningitis contains much higher levels of chemokines,
including CXCL8 [28].
To ensure that cytokine secretion by SspA-stimulated
macrophages did not result from LPS contaminants,
polymyxin B, an LPS-reacting molecule [29], was
included durind stimulation. Results showed that poly-
myxin B, did not inhibit cytokine secretion thus suggest-
ing that this stimulation is induced by the recombinant
SspA protease only. This ability of the recombinant
SspA to induced cytokine secretion in macrophages was
found to be highly specific since it was not observed
with the pancreatic trypsin used as a control.
Proteases can induce the secretion of inflammatory
mediators in mammalian cells by two ways: action on
proteinase-activated receptors (PARs) or through a non-
proteolytic mechanism, involving the mitogen-activated
protein kinases (MAPK) [30,31]. Several proteases have
been identified as signaling molecules that specifically
regulate members of PARs, a family of seven transmem-
brane domains G-protein-coupled receptors [32,33].
This family includes four members: PAR-1, PAR-3 and
PAR-4 are receptors for thrombin, trypsin or cathepsin
G, while PAR-2 is resistant to thrombin, but can be acti-
vated by trypsin, mast cell tryptase [30,34-36]. Since the
heat-inactivated SspA still possessed the capacity to
induce cytokine secretion in macrophages, the involve-
ment of PARs could be ruled out. We thus investigated
whether the SspA may induce cytokine secretion
through activation of MAP kinases. More specifically,
there are three major groups of MAPK in mammalian
cells: the extracellular signal-regulated protein kinase
Table 1 Effect of heat treatment or the presence of polymyxin B on cytokine secretion by PMA-differentiated U937
macrophages stimulated with the recombinant SspA (33 μg/ml) of S. suis
Conditions Amount secreted (pg/ml)
CCL5 IL-6 CXCL8
Control (no stimulation) 2081 ± 14 100 ± 1 3170 ± 9
Recombinant SspA of S. suis 2370 ± 61* 1922 ± 31* 108557 ± 620*
Heat-inactivated recombinant SspA of S. suis 72409 ± 848* 2111 ± 71* 102287 ± 1062*
Recombinant SspA of S. suis + polymyxin B 2081 ± 32 2099 ± 254* 107446 ± 590*
The data are the means ± SD of triplicate assays for three separate experiments. Asterisks indicate a significant difference in comparison with the unstimulated
control at P < 0.01.
Table 2 Cytokine secretion by PMA-differentiated U937 macrophages following stimulation with S. suis P1/7 and its
SspA deficient mutant G6G
Strain Amount secreted of cytokines (pg/ml)
IL-1b TNF-a IL-6 CXCL8 CCL5
Control 51 ± 3 217 ± 2 10 ± 1 5245 ± 432 2116 ± 4
S. suis P1/7 161 ± 8 1800 ± 11 1160 ± 21 611000 ± 756 13355 ± 564
S. suis G6G 120 ± 3* 1030 ± 14* 690 ± 6* 653000 ± 634* 15664 ± 34*
The data are the means ± SD of triplicate assays for three separate experiments. Asterisks indicate a significant difference in cytokine secretion by macrophages
stimulated with the SspA deficient mutant (G6G) in comparison with the parental strain at P < 0.01.
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kinase (JNK) [31]. Our results obtained by including
kinase inhibitor during stimulation of macrophages with
the recombinant SspA suggested that the production of
CCL5 and CXCL8 was regulated by p38 MAPK while
the production of IL-6 was mostly regulated by JNK.
MAPK are known as key regulators for the synthesis of
numerous cytokines, chemokines, and other inflamma-
tory mediators [31]. Previous studies also suggested a
similar involvement of the MAPK regulatory pathway in
inflammatory responses induced by S. suis [37-39]. In
agreement with our observations, the cysteine protei-
nases of Porphyromonas gingivalis was also reported to
use the MAPK transduction pathway to induce cytokine
secretion in macrophages [40] and fibroblasts [41].
Our data showed that the amounts of CCL5 in the con-
ditioned medium of macrophages stimulated with the
heat-inactivated recombinant SspA was higher compared
to that detected following stimulation with the active SspA.
This suggests that SspA may degrade this cytokine. Using
ELISA, we clearly showed the capacity of the recombinant
SspA to degrade dose-dependently CCL5. Since CCL5 pos-
sesses chemotactic activity for immune cells, its inactiva-
tion by the SspA may allow S. suis to avoid and delay
neutrophil attraction and activation. Cytokine degradation
by proteases is a phenomenon well described in group A
streptococci. Sumby et al., reported the ability of Strepto-
coccus pyogenes SpyCEP to reduce neutrophil activity
though cleavage and inactivation of the human chemokine
granulocyte chemotactic protein 2 (GCP-2) [42]. In addi-
tion, the protease of S. pyogenes was reported to cleave
CXCL8 [42,43]. Moreover, Bryan et al., showed that Strep-
tococcus agalactiae CspA, inactivates the CXC chemokines
GRO-alpha, GRO-beta, GRO-gamma, neutrophil-activating
peptide 2 (NAP-2), and GCP-2 [44]. Lastly, the subtilisin-
like protease SufA of Finegoldia magna, that shares many
properties with the SspA of S. suis, has been shown to
degrade the chemokine MIG/CXCL9 [45]. Degradation of
CXCL8 by S. suis has been previously reported [46]. The
protease involved in the cleavage of CXCL8 was different
from the cell wall-anchored SspA since it was found to be
secreted by S. suis [46].
T h ea b i l i t yo fS s p At oi n d u c ec y t o k i n es e c r e t i o ni n
macrophages was confirmed using a mutant of S. suis
deficient in SspA expression. The secretion of IL-1b,
TNF-a, and IL-6 was significantly less important when
macrophages were stimulated with cells of SspA mutant
compared to the stimulation with the parental strain.
This strongly supports the contribution of SspA in
S. suis induced inflammatory response in macrophages.
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Figure 2 CCL5, IL-6 and CXCL8 degradation by the recombinant SspA of S. suis. A value of 100% was assigned to the amounts of
cytokines detected in the absence of SspA. The data are means ± SD of triplicate assays from three separate experiments. Asterisks indicate a
significant difference in comparison with the control (no SspA) at P < 0.01.
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higher following stimulation with the SspA-deficient
mutant compared to the parental strain. This result sup-
ports the capacity of the recombinant SspA protease to
degrade CCL5. The fact that no decrease in CXCL8
secretion was observed following stimulation of macro-
phages with the SspA-deficient mutant suggests that
other cell surface components of S. suis, such as the cell
wall [46], are likely to play a more important role in
CXCL8 secretion than the SspA protease.
Conclusions
In conclusion, this study bought evidence that the subti-
lisin-like protease SspA of S. suis m a ym o d u l a t et h e
inflammation state associated with meningitis. It may
either induce the secretion of important pro-inflamma-
tory cytokines or, when present at high concentration,
cause the degradation of selected cytokines, such as
CCL5 and IL-6.
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